{
    "clinical_study": {
        "@rank": "84162", 
        "arm_group": {
            "arm_group_label": "Prostaglandin Analogues", 
            "arm_group_type": "Experimental", 
            "description": "The patients will receive a single daily drop of bimatoprost for six months."
        }, 
        "brief_summary": {
            "textblock": "Prostaglandin analogues eye drops are common and effective treatment for decreasing\n      Intra-Ocular Pressure (IOP) in Glaucoma patients. A number of recently published case\n      reports have documented periorbital fat atrophy following treatment by prostaglandin\n      analogues. In this study the investigators want to use this side-effect of prostaglandin\n      analogues for the treatment of orbital and periocular fat proliferation in inactive Thyroid\n      eye disease (TED) patients, as a conservative substitute for surgical intervention."
        }, 
        "brief_title": "Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues", 
        "condition": "Thyroid Associated Ophthalmopathies", 
        "condition_browse": {
            "mesh_term": [
                "Eye Diseases", 
                "Thyroid Diseases", 
                "Graves Ophthalmopathy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inactive TED (Clinical Activity Score below 3)\n\n          -  Significant exophthalmos or orbital fat expansion.\n\n        Exclusion Criteria:\n\n          -  Previous prostaglandin analogues treatment due to glaucoma\n\n          -  Known prostaglandin analogues sensitivity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155049", 
            "org_study_id": "TED-01", 
            "secondary_id": "Thyroid eye disease"
        }, 
        "intervention": {
            "arm_group_label": "Prostaglandin Analogues", 
            "description": "The patients will receive a single daily drop of bimatoprost for six months.", 
            "intervention_name": "bimatoprost 0.03%", 
            "intervention_type": "Drug", 
            "other_name": "Lumigan (Allergan, Inc, Irvine, California)"
        }, 
        "intervention_browse": {
            "mesh_term": "Bimatoprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TED", 
            "Prostaglandin Analogues"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "mayae2@clalit.org.il", 
                "last_name": "Maya Eiger, MD", 
                "phone": "+972-3-9376017"
            }, 
            "facility": {
                "address": {
                    "city": "Petach Tikva", 
                    "country": "Israel"
                }, 
                "name": "Ophthalmology clinics, Rabin Medical Center"
            }, 
            "investigator": {
                "last_name": "Maya Eiger, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.", 
        "other_outcome": {
            "description": "To measure the reversibility of bimatoprost treatment on the amount of soft tissue and exophthalmos at the end of the treatment course and 3 months post cessation. We shall perform the same measurements as described in the Primary Outcome section.", 
            "measure": "Bimatoprost effect reversibility after treatment cessation.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "mayae2@clalit.org.il", 
            "last_name": "Maya Eiger, MD", 
            "phone": "+972-3-9376107"
        }, 
        "overall_official": {
            "affiliation": "Rabin Medical Center", 
            "last_name": "Maya Eiger, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To document the effect of bimatoprost treatment on the amount of soft tissue and exophthalmos in inactive TED patients. The following measurements will be performed pre, post and during treatment: orbital ultrasound (measuring the eyebrow fat, retro-orbicularis oculi fat and retrobulbar fat), Hertel exophthalmometry and Marginal Reflex Distance (MRD). The external appearance would be also documented by face picture.", 
            "measure": "Bimatoprost effect on soft tissue amount and exophthalmos in inactive TED patients.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155049"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "Maya Eiger", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Determine the safety of bimatoprost treatment by estimating the probabilities of adverse outcomes. To estimate these probabilities we shall count the number of participants suffering from known side-effects of prostaglandin analogues such as increased eyelash growth and darkening of the periocular skin and iris; as well as any other side-effects observed during treatment.", 
            "measure": "Number of participants with adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rabin Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}